Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

42.80 +0.12 (+0.29%)

Streaming Delayed Price Updated: 3:43 PM EDT, Aug 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

42 43 Next >

Is Sanofi Stock a Buy Now? ↗

March 25, 2023

The pharma giant has outperformed the broader market over the past 12 months.

Via The Motley Fool

Stock Market Split As Fed Hikes Rates, Banks Keep Tumbling; Nvidia, On Holding In Focus: Weekly Review ↗

March 24, 2023

The major indexes showed volatile, divergent action.

Via Investor's Business Daily

Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In ↗

March 24, 2023

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the Phase 3 trial of Dupixent (dupilumab), developed with Sanofi (NASDAQ: SNY), for uncontrolled chronic obstructive pulmonary disease (COPD) met...

Via Benzinga

Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration ↗

March 24, 2023

Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares surged on Thursday after the companies announced primary and all key secondary endpoints were met in a Phase 3 trial...

Via Benzinga

Looking Into Sanofi's Recent Short Interest ↗

March 23, 2023

Via Benzinga

Sanofi (NASDAQ: SNY) Highlighted for Surprising Price Action

March 23, 2023

Via Investor Brand Network

Why Shares of Regeneron Are Rising Thursday ↗

March 23, 2023

Regeneron released positive phase 3 trial results for its therapy Dupixent.

Via The Motley Fool

Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung' ↗

March 23, 2023

The companies' Dupixent reduced exacerbations by 30%.

Via Investor's Business Daily

REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data ↗

March 23, 2023

Regeneron Pharmaceuticals (REGN) stock is on the rise Thursday after the company released its latest clinical trial data on Dupixent.

Via InvestorPlace

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)

March 23, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Apple Jumps Movie Production Bandwagon, Billionaire Jim Ratcliffe Bids For Manchester United, Elon Musk Seeks Funding For SpaceX From Middle-Eastern Fund: Today's Top Stories ↗

March 23, 2023

Bloomberg

Via Benzinga

Acer Therapeutics' Product Acquired From Sanofi Fails In Menopause Study ↗

March 17, 2023

Via Benzinga

2 Top Biotech Stocks to Buy Right Now ↗

March 15, 2023

These two companies are showering shareholders with market-topping payouts.

Via The Motley Fool

Why Regeneron Pharmaceuticals And Sanofi Shares Are Trading Higher Today ↗

March 23, 2023

Sanofi-Regeneron stocks are trading higher today after their blockbuster drug aced the pivotal COPD trial.

Via Benzinga

Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories ↗

March 20, 2023

Reuters

Via Benzinga

Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case' ↗

March 20, 2023

Via Benzinga

Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis

March 18, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Provention Bio's $2.9B Acquisition - A Strategic Fit For Sanofi ↗

March 13, 2023

Via Benzinga

Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review ↗

March 17, 2023

A market rally is underway, but bank stocks kept tumbling.

Via Investor's Business Daily

SVB Financial Officially Files For Bankruptcy, Yellen, Powell & Dimon Behind First Republic Bank's $30B Lifeline, Playboy's $5M Loss On Ethereum: Today's Top Stories ↗

March 17, 2023

Benzinga

Via Benzinga

Three Is Company - Sanofi Follows Lilly, Novo Nordisk, Slashes Insulin Product Price By 78% ↗

March 17, 2023

Via Benzinga

Why Provention Bio Stock Skyrocketed 256% This Week ↗

March 16, 2023

Provention Bio is currently a partner of Sanofi. It should soon become a part of the big French drugmaker.

Via The Motley Fool

What's Going On With Sanofi Stock After Hours? ↗

March 16, 2023

Sanofi SA (NASDAQ: SNY) is buzzing in Thursday's after-hours session after the company said it will cut the list price of its most widely prescribed insulin in the United States

Via Benzinga

Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners ↗

March 13, 2023

On a volatile market day, companies are still looking for smart combinations.

Via The Motley Fool

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qualtrics (Nasdaq - XM), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)

March 13, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Sanofi (NASDAQ: SNY) Set to Acquire Provention Bio (NASDAQ: PRVB) for $2.9 Billion

March 13, 2023

Provention Bio, Inc. (NASDAQ: PRVB) is engaged as a commercial-stage biopharmaceutical company, which is focused on the research, development and

Via Spotlight Growth

Pfizer Officially Nabs Seagen For $43 Billion; Provention Soars On Sanofi Deal ↗

March 13, 2023

Pfizer expects Seagen to add at least $10 billion to its topline in 2030.

Via Investor's Business Daily

Why Provention Bio Stock Is Rocketing Past 52-Week Highs Today ↗

March 13, 2023

Provention Bio Inc (NASDAQ: PRVB) shares are rocketing higher Monday after Sanofi (NASDAQ: SNY) announced plans to acquire the biopharmaceutical company.

Via Benzinga

Why Is Provention Bio (PRVB) Stock Up 263% Today? ↗

March 13, 2023

Provention Bio (PRVB) stock is rocketing higher on Monday following news that Sanofi (SNY) is acquiring the company for $2.9 billion.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

March 13, 2023

We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday!

Via InvestorPlace

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

42 43 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sanofi - American Depositary Shares (NQ:SNY)

All News about Sanofi - American Depositary Shares

Starting at /week.